Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,585 signal articles · 328 in last 24h · 112,405 total before filter · latest 40m ago
328last 24h
2141last 7d
379● bullish (7d)
188● bearish (7d)
204publishers
AllMacro296Earnings1216M&A91Regulatory23Product13Analyst20
✕ clear all filtersticker: CVSsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
CVS’s Turnaround Faces Its Next Test
Barrons.com8d agoneutral
CVS’s Turnaround Faces Its Next Test

CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.

FTC Reaches Settlement With CVS Health Over Insulin Prices
Barrons.com29d agoneutral
FTC Reaches Settlement With CVS Health Over Insulin Prices

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.